1. In vivo testing in porcine model demonstrates abluminal coating is absorbed after 6 to 9 months – Data on file at Biosensors International

2. LEADERS is a Biosensors International study. www.clinicaltrial.gov – NCT00389220

3. P. W. Serruys, LEADERS: 5-year follow-up from a prospective, randomized trial of Biolimus A9-eluting stents with a biodegradable polymer vs. sirolimus-eluting stents with a durable polymer in coronary artery disease, oral abstract presentation, TCT 2012

Data on file at Biosensors International

BioMatrix NeoFlex™ drug eluting stent system is CE approved.

Biosensors International Group, Ltd. licenses its proprietary BA9™ drug and PLA technology to Terumo Corporation (Nobori®).

BioMatrix NeoFlex™ stent is indicated in diabetics, STEMI and ACS patients for stent lengths up to 28 mm.

LEADERS is a Biosensors International study. www.clinicaltrial.gov - NCT00389220.

CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings and instructions for use can be found in the product labeling supplied with each device.

Biosensors International Group, Ltd. owns the proprietary BA9™ drug and PLA technology in Terumo Corporation (Nobori®).

The BioMatrix NeoFlex™ stent is indicated in diabetics, STEMI and ACS patients for stent lengths up to 28 mm.

CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings and instructions for use can be found in the product labeling supplied with each device.

BioMatrix NeoFlex, BioMatrix Flex, Juno, Quadrature Link, Biolimus A9 and BA9 are trademarks or registered trademarks of Biosensors International Group, Ltd. in the United States and other countries.

All cited trademarks are the property of their respective owners.

Not available for sale in the United States and certain other countries.

© 2013 Biosensors International Group, Ltd. All rights reserved

www.biosensors.com

<table>
<thead>
<tr>
<th>Ordering Information</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Stent Diameter (mm)</strong></td>
</tr>
<tr>
<td><strong>Stent Length (mm)</strong></td>
</tr>
<tr>
<td>2.50</td>
</tr>
<tr>
<td>2.75</td>
</tr>
<tr>
<td>3.00</td>
</tr>
<tr>
<td>3.50</td>
</tr>
<tr>
<td>4.00</td>
</tr>
</tbody>
</table>

* In vivo testing in porcine model demonstrates abluminal coating is absorbed after 6 to 9 months – Data on file at Biosensors International
Biosensors brings you the newest member of the BioMatrix™ family: BioMatrix NeoFlex.

With the LEADERS 1 trial 5-year results BioMatrix Flex™ achieved Gold Standard status in biodegradable technology.

Now BioMatrix NeoFlex with an enhanced stent delivery system, brings exceptional performance in complex lesions and challenging anatomy.

BioMatrix NeoFlex: one step beyond

When it comes to biodegradable polymer technology, Biosensors has developed the highest level of expertise and delivered the best results in terms of safety and efficacy, as demonstrated by the landmark LEADERS 2 trial. The additional improvement with NeoFlex is provided by an even better delivery system.

Proven efficacy of the Biolimus A9 drug

BA9 differs from common limus drugs by having increased lipophilicity properties. BA9 lipophilicity offers improved characteristics for a drug intended for local action on vascular SMC, including rapid transfer to cells in the vessel wall coupled with limited systemic exposure.